ICCC Q4 2022 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-28.2% YoY

Gross Profit

$2M40.4% margin

Operating Income

-$2M-41.8% margin

Net Income

-$2M-42.6% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-18.5%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$3M

Stock-Based Comp.

$65,395

Balance Sheet

Total Assets

$45M

Total Liabilities

$14M

Stockholders' Equity

$30M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-28.2%
Gross Profit	$2M	$3M	-38.3%
Operating Income	-$2M	$145,412	-1223.5%
Net Income	-$2M	$74,134	-2349.8%